Abstract:Objective To evaluate the efficacy and long-term safety of autologous bone marrow stem cells(ABMSC)transplantation in patients with hepatitis B virus(HBV)-associated decompensated liver cirrhosis.Methods This was an open-label,prospective matched case-control study.Thirty patients with HBV-associated decompensated liver cirrhosis hospitalized at the Third Affiliated Hospital of Sun Yat-Sen University from January 2005 to June 2010 were collected and infused with stem cells(stem cell group). Another thirty patients in control group were matched according to baseline characteristics and treated with standard medicine therapy.The patients in stem cell group were treated with stem cells infusion by hepatic artery or portal vein based on standard medicine therapy.All the patients were followed up for 5 to 10 years after surgery. Biochemical indicators were evaluated within the first 48 weeks after transplantation.The complications of cirrhosis and the cumulative incidence rate of hepatocellular carcinoma(HCC)were observed.Measurement data with normal distribution were analyzed by t test. Measurement data with non-normal distribution were compared by Mann-Whitney test.Count data were compared by χ2 test.The cumulative incidence rate of HCC development was compared by Kaplan-Meier analysis.Results The bone marrow aspiration and transplantation surgery were well tolerated in all patients in stem cell group.No complication related to stem cell transplantation therapy was observed. The levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBil) and prothrombin time(PT)decreased,albumin level increased,while model for end-stage liver disease (MELD)scores decreased in both groups after treatment.Serum albumin level in stem cell group increased and ALT level decreased markedly at week 4,compared with that in control group at week 4(Z=2.188,P=0.029,Z=3.296,P=0.001,respectively).In stem cell group,21 patients received stem cells transplantation by hepatic artery and 9 patients by portal vein.Biochemical indicators were improved in all patients compared to baseline.However,there was no statistically significant differences between hepatic artery group and portal vein group.The median follow-up time was 6 years.Two patients in stem cell group and 1 patient in control group died(χ2=0.351,P=0.554).Six patients in stem cell group (20.0%)and 11 patients(36.7%)in control group developed HCC.There was no significant differences in the cumulative incidence rate of HCC between two groups(χ2= 0.148,P= 0.701).Hepatorenal syndrome did not development in either group.There were no statistically significant differences in the rates of complications including spontaneous peritonitis,hepatic encephalopathy and gastrointestinal hemorrhage between two groups after 5 to 10 years of follow-up(χ2=0.162,P=0.688,χ2=1.071,P=0.301,χ2=1.071,P=0.301,respectively).Conclusion ABMSC transplantation in patients with HBV-associated decompensated liver cirrhosis improves liver function transiently and has long-term safety.

[Effects of Autologous Peripheral Stem Cell Transplantation on Acoustic Radiation Force Impulse in Patients with HBV-related Decompensated Cirrhosis].

Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis

A Clinic Study on Long-term Efficacy and Safety of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Decompensated Hepatitis B Cirrhosis

The efficacy and long-term safety of autologous bone marrow stem cells transplantation in patients with hepatitis B virus-associated decompensated liver cirrhosis

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Are Autologous Bone Marrow Stem Cell Transplantation and Transcatheter Arterial Embolization the Best Choices for Patients with Hepatocellular Carcinoma and Hepatic Dysfunction? Report of a Case

Antiviral Therapy Improves Postoperative Survival of Patients with HBV-related Hepatocellular Carcinoma.

Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Cirrhosis

Autologous peripheral stem cell transplantation in the treatment of decompensated hepatic cirrhosis

Transplantation of Autologous Bone Marrow Stem Cells in Treatment of Patients with Decompensated Cirrhosis

Transplantation of Autologons Bone Marrow Stem Cells Via Hepatic Artery for 40 Patients with Decompensated Cirrhosis

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

Therapeutic Potential of Peripheral Blood Stem Cell Transplantation in One Cirrhotic Patient Caused by Hbv Combined with Hcv

Effects Of Allogeneic Mesenchymal Stem Cell Transplantation In The Treatment Of Liver Cirrhosis Caused By Autoimmune Diseases

Controlled Trials in Hepatitis B Virus-Related Decompensate Liver Cirrhosis: Peripheral Blood Monocyte Transplant Versus Granulocyte-Colony-Stimulating Factor Mobilization Therapy

Curative Effect of Combined Lamivudine, Adefovir Dipivoxil, and Stem Cell Transplantation on Decompensated Hepatitis B Cirrhosis

Therapeutic Effect of Autologous Bone Marrow Cells Injected into the Liver under the Guidance of B‑ultrasound in the Treatment of HBV‑related Decompensated Liver Cirrhosis.

[Immunoregulation of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Hepatitis B-related End-Stage Liver Disease].

The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study

Clinical study on optimization scheme of autologous bone marrow stem cell transplantation for decompensated cirrhosis

Effect and mechanism of Bone Marrow Mesenchymal Stem Cells on autologous lymphocyte proliferation in patients with decompensated liver cirrhosis